000			02365 a2200661 4500
005			20250513185945.0
264		0	_c19990812
008			199908s 0 0 eng d
022			_a0008-5472
040			_aNLM _beng _cNLM
100	1		_aWessel, I
245	0	0	_aHuman small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform. _h[electronic resource]
260			_bCancer research _cJul 1999
300			_a3442-50 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAdenosine Triphosphate _xmetabolism
650	0	4	_aAmino Acid Sequence
650	0	4	_aAmino Acid Substitution
650	0	4	_aAmsacrine _xpharmacology
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Agents _xchemistry
650	0	4	_aBinding Sites
650	0	4	_aCHO Cells
650	0	4	_aCarcinoma, Small Cell _xdrug therapy
650	0	4	_aCatalysis _xdrug effects
650	0	4	_aConsensus Sequence
650	0	4	_aCricetinae
650	0	4	_aCricetulus
650	0	4	_aDNA Damage
650	0	4	_aDNA Mutational Analysis
650	0	4	_aDNA Topoisomerases, Type II _xgenetics
650	0	4	_aDNA, Neoplasm _xgenetics
650	0	4	_aDNA, Single-Stranded _xgenetics
650	0	4	_aDrug Resistance, Neoplasm _xgenetics
650	0	4	_aEnzyme Inhibitors _xpharmacology
650	0	4	_aEtoposide _xpharmacology
650	0	4	_aHumans
650	0	4	_aLung Neoplasms _xdrug therapy
650	0	4	_aMolecular Sequence Data
650	0	4	_aMutagenesis, Site-Directed
650	0	4	_aPoint Mutation
650	0	4	_aProtein Isoforms _xantagonists & inhibitors
650	0	4	_aRazoxane _xchemistry
650	0	4	_aRecombinant Fusion Proteins _xmetabolism
650	0	4	_aSaccharomyces cerevisiae _xgenetics
650	0	4	_aStructure-Activity Relationship
650	0	4	_aThiobarbiturates _xpharmacology
650	0	4	_aTopoisomerase II Inhibitors
650	0	4	_aTumor Stem Cell Assay
700	1		_aJensen, L H
700	1		_aJensen, P B
700	1		_aFalck, J
700	1		_aRose, A
700	1		_aRoerth, M
700	1		_aNitiss, J L
700	1		_aSehested, M
773	0		_tCancer research _gvol. 59 _gno. 14 _gp. 3442-50
999			_c10374629 _d10374629